Chemours Co (NYSE:CC) VP Amy Trojanowski sold 10,129 shares of Chemours stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $39.10, for a total value of $396,043.90. Following the sale, the vice president now directly owns 54,795 shares of the company’s stock, valued at $2,142,484.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amy Trojanowski also recently made the following trade(s):

  • On Friday, March 15th, Amy Trojanowski sold 9,049 shares of Chemours stock. The stock was sold at an average price of $39.10, for a total value of $353,815.90.
  • On Friday, March 1st, Amy Trojanowski sold 13,536 shares of Chemours stock. The stock was sold at an average price of $38.63, for a total value of $522,895.68.

NYSE:CC opened at $37.89 on Monday. Chemours Co has a 1 year low of $25.17 and a 1 year high of $53.25. The company has a quick ratio of 1.26, a current ratio of 1.93 and a debt-to-equity ratio of 3.88. The stock has a market capitalization of $6.46 billion, a price-to-earnings ratio of 6.68, a price-to-earnings-growth ratio of 0.53 and a beta of 2.31.

Chemours (NYSE:CC) last posted its earnings results on Thursday, February 14th. The specialty chemicals company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.01. Chemours had a return on equity of 98.83% and a net margin of 14.99%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period in the previous year, the firm earned $1.19 earnings per share. The company’s revenue was down 7.0% on a year-over-year basis. As a group, equities research analysts anticipate that Chemours Co will post 4.69 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Wednesday, February 27th were paid a $0.25 dividend. The ex-dividend date of this dividend was Tuesday, February 26th. This represents a $1.00 dividend on an annualized basis and a yield of 2.64%. Chemours’s payout ratio is 17.64%.

CC has been the subject of a number of analyst reports. Citigroup raised Chemours from a “neutral” rating to a “buy” rating in a research note on Friday, January 4th. HSBC initiated coverage on Chemours in a research note on Tuesday, January 8th. They set a “buy” rating and a $52.00 price objective for the company. Barclays reaffirmed a “buy” rating and set a $48.00 price objective on shares of Chemours in a research note on Tuesday, January 15th. Zacks Investment Research raised Chemours from a “sell” rating to a “hold” rating in a research note on Tuesday, December 11th. Finally, SunTrust Banks lifted their price objective on Chemours to $40.00 and gave the stock a “hold” rating in a research note on Tuesday, February 19th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. Chemours currently has an average rating of “Hold” and a consensus price target of $48.13.

A number of large investors have recently bought and sold shares of CC. Financial Architects Inc boosted its position in shares of Chemours by 39.2% during the fourth quarter. Financial Architects Inc now owns 1,421 shares of the specialty chemicals company’s stock worth $40,000 after buying an additional 400 shares during the period. Lavaca Capital LLC acquired a new position in shares of Chemours during the fourth quarter worth about $44,000. FUKOKU MUTUAL LIFE INSURANCE Co boosted its position in shares of Chemours by 357.1% during the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 3,200 shares of the specialty chemicals company’s stock worth $90,000 after buying an additional 2,500 shares during the period. Oregon Public Employees Retirement Fund boosted its position in shares of Chemours by 3,583.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,675,256 shares of the specialty chemicals company’s stock worth $95,000 after buying an additional 2,602,624 shares during the period. Finally, Penserra Capital Management LLC boosted its position in shares of Chemours by 122.6% during the fourth quarter. Penserra Capital Management LLC now owns 4,167 shares of the specialty chemicals company’s stock worth $116,000 after buying an additional 2,295 shares during the period. 79.49% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2019/03/18/amy-trojanowski-sells-10129-shares-of-chemours-co-cc-stock.html.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Story: Debt-To-Equity Ratio

Insider Buying and Selling by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.